Answers are grounded in this paper and cite their sources.
Investigates immunomodulatory drugs to improve outcomes in tuberculous meningitis, suggesting effective therapies.
Tuberculous meningitis (TB meningitis) is a major cause of death and neurological deficit despite recommended antibiotic and corticosteroid treatments, primarily due to dysregulated neuroinflammation. Here, we investigate a diverse panel of 12 immunomodulatory drugs as host-directed treatments (HDTs) for TB meningitis utilizing a cross-species framework comprising studies in a mouse model of TB meningitis with clinical endpoints, and parallel mechanistic studies in a newly developed immune-vascularized human brain organoid model of TB meningitis and peripheral blood mononuclear cells (PBMCs) from patients with TB meningitis. Imatinib, bestatin, roflumilast, palacaparib, thalidomide/pomalidomide and semaglutide outperform the current standard of care by reducing mortality and/or neurological deficits in mice via suppression of neuroinflammation. Importantly, these HDTs significantly reduce microglial activation in Mycobacterium tuberculosis-infected human brain organoids and attenuate proinflammatory cytokines, particularly IFNγ within CD4+ T-cells in patient-derived PBMCs. These findings highlight the potential of targeted HDTs to improve outcomes in TB meningitis and warrant clinical investigation. Here, the authors investigate a diverse panel of 12 immunomodulatory drugs as host directed treatments (HDTs) for tuberculous (TB) meningitis in a preclinical model, a human brain organoid model and cells collected from patients with TB meningitis.
No takes yet. Share an insight, caveat, or question.
Ruiz-Gonzalez et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: